title: Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma.
authors.affiliation: Department of Urology, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Aso
authors.forename: H
authors.initials: H
authors.lastname: Tazaki
authors.forename: T
authors.initials: T
authors.lastname: Umeda
authors.forename: K
authors.initials: K
authors.lastname: Marumo
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007564:Japan; D007680:Kidney Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins